Skip to main content

Horizon Therapeutics PLC (HZNP)

NASDAQ: HZNP · IEX Real-Time Price · USD
117.00
+0.55 (0.47%)
After-hours:Oct 22, 2021 4:59 PM EDT
116.45
-0.01 (-0.01%)
At close: Oct 22, 4:00 PM
Market Cap26.31B
Revenue (ttm)2.56B
Net Income (ttm)518.16M
Shares Out225.12M
EPS (ttm)2.19
PE Ratio53.20
Forward PE19.80
Dividendn/a
Ex-Dividend Daten/a
Volume715,356
Open116.89
Previous Close116.46
Day's Range115.70 - 117.65
52-Week Range66.41 - 117.65
Beta1.04
AnalystsBuy
Price Target134.75 (+15.7%)
Est. Earnings DateNov 3, 2021

About HZNP

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI ...

IndustryPharmaceuticals
IPO DateJul 28, 2011
Employees1,695
Stock ExchangeNASDAQ
Ticker SymbolHZNP
Full Company Profile

Financial Performance

In 2020, HZNP's revenue was $2.20 billion, an increase of 69.26% compared to the previous year's $1.30 billion. Earnings were $389.80 million, a decrease of -31.98%.

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for HZNP stock is "Buy." The 12-month stock price forecast is 134.75, which is an increase of 15.71% from the latest price.

Price Target
$134.75
(15.71% upside)
Analyst Consensus: Buy

News

Horizon Therapeutics plc Named to Newsweek's List of the Most Loved Workplaces for 2021

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that is has been named to Newsweek's inaugural Most Loved Workplaces list for 2021, ranking among the top 100 companies r...

1 day ago - Business Wire

Newly Published Data Continue to Support Long-Term Efficacy of TEPEZZA® (teprotumumab-trbw) for Thyroid Eye Disease (...

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics announced data supporting the long-term efficacy of TEPEZZA (teprotumumab-trbw) for the treatment of Thyroid Eye Disease (TED).

2 days ago - Business Wire

3 Reasons Why Growth Investors Shouldn't Overlook Horizon Therapeutics (HZNP)

Horizon Therapeutics (HZNP) possesses solid growth attributes, which could help it handily outperform the market.

3 days ago - Zacks Investment Research

This 1 Medical Stock Could Beat Earnings: Why It Should Be on Your Radar

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

1 week ago - Zacks Investment Research

New Data Reinforce the Relationship Between B-Cell Depletion and Improved Outcomes in People Receiving UPLIZNA® (ineb...

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics announced results from a new analysis of UPLIZNA® (inebilizumab-cdon) in neuromyelitis optica spectrum disorder (NMOSD).

1 week ago - Business Wire

New TEPEZZA® (teprotumumab-trbw) Data to be Presented at the American Academy of Ophthalmology (AAO) 2021 Annual Meeting

DUBLIN--(BUSINESS WIRE)--New TEPEZZA® (teprotumumab-trbw) Data to be Presented at the American Academy of Ophthalmology (AAO) 2021 Annual Meeting

1 week ago - Business Wire

Horizon Therapeutics plc to Release Third-Quarter 2021 Financial Results and Host Webcast on Nov. 3, 2021

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) announced today that its third-quarter 2021 financial results will be released on Wednesday, Nov. 3, 2021. Following the announcement, Ho...

1 week ago - Business Wire

Horizon Therapeutics plc Named One of the 2021 Top 100 Adoption-Friendly Workplaces by the Dave Thomas Foundation for...

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that is has been named one of the Top 100 Adoption-Friendly Workplaces in the United States by the Dave Thomas Foundation...

2 weeks ago - Business Wire

New Analysis Published in Multiple Sclerosis Journal Assesses Long-Term Use of UPLIZNA® (inebilizumab-cdon) for the T...

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics announced a new analysis of UPLIZNA® (inebilizumab-cdon) for the treatment of NMOSD published in Multiple Sclerosis Journal.

2 weeks ago - Business Wire

Horizon Therapeutics plc Announces New UPLIZNA® (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (N...

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics announced UPLIZNA® (inebilizumab-cdon) data in neuromyelitis optica spectrum disorder (NMOSD) to be presented at ECTRIMS 2021.

2 weeks ago - Business Wire

Horizon Therapeutics plc Announces New Development Programs at Virtual R&D Day

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) will present an overview of its pipeline, including five new development programs for investigational medicines, daxdilimab (HZN-7734) an...

3 weeks ago - Business Wire

7 Biotech Stocks Entering the Golden Boom Phase

These biotech stocks offer a more mature take on an otherwise risky sector. These companies already have successes under their belt.

Other symbols:ABBVJNJLLYMRKNVSREGN
3 weeks ago - InvestorPlace

4 Top Biotech Stocks to Watch as Economic Recovery Picks Up Pace

New drug approvals and focus on coronavirus treatments should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position REGN, MRNA, VRTX, ...

Other symbols:MRNAREGNVRTX
1 month ago - Zacks Investment Research

Horizon Therapeutics plc Announces Agenda for Virtual R&D Day for Investors and Analysts on Sept. 29, 2021

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced the agenda for its virtual R&D Day for investors and analysts on Sept. 29, 2021. During the event, Horizon's R&D leadersh...

1 month ago - Business Wire

Horizon Therapeutics plc Announces Data Showing UPLIZNA® (inebilizumab-cdon) Also Produces Rapid and Sustained B-Cell...

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc announces data for UPLIZNA® (inebilizumab-cdon) in African Americans with neuromyelitis optica spectrum disorder (NMOSD).

1 month ago - Business Wire

Horizon Therapeutics plc Announces New Genetic Counselor Curated Algorithms and Next-Generation Sequencing Data as Wi...

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP), in collaboration with MIT Solve, a marketplace for social impact innovation, is proud to announce two winning solutions of this year's H...

1 month ago - Business Wire

HemoShear Therapeutics Advancing Several Novel Compounds for Horizon Therapeutics plc Gout Discovery Pipeline

CHARLOTTESVILLE, Va., Sept. 21, 2021 /PRNewswire/ -- HemoShear Therapeutics, Inc., a privately held clinical stage biotechnology company, has earned a milestone payment for the advancement of potential ...

1 month ago - PRNewsWire

Horizon Therapeutics plc Named One of the 2021 Best Workplaces for Women™ by Fortune and Great Place to Work®

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has been named to the 2021 Best Workplaces for Women™ list for the first time by Fortune and Great Place to Work®...

1 month ago - Business Wire

Horizon Therapeutics reports record quarter

Tim Walbert, Horizon Therapeutics Chairman and CEO, joins The Exchange to discuss his company's record run and the non-Covid pharmaceuticals the company is working on. For access to live and exclusive v...

1 month ago - CNBC Television

3 Reasons Why Horizon Therapeutics (HZNP) Is a Great Growth Stock

Horizon Therapeutics (HZNP) could produce exceptional returns because of its solid growth attributes.

1 month ago - Zacks Investment Research

Is Horizon (HZNP) a Great Growth Stock?

If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Horizon (HZNP).

1 month ago - Zacks Investment Research

Horizon (HZNP) Begins Phase IV Study on Tepezza for Chronic TED

Horizon (HZNP) enrolls the first patient in a phase IV study evaluating the safety and efficacy of Tepezza for the treatment of chronic (inactive) thyroid eye disease.

1 month ago - Zacks Investment Research

Horizon Therapeutics plc Initiates Randomized Controlled Clinical Trial Evaluating TEPEZZA® (teprotumumab-trbw) for t...

DUBLIN--(BUSINESS WIRE)--Horizon initiates a clinical trial evaluating TEPEZZA® (teprotumumab-trbw) for the treatment for chronic (inactive) Thyroid Eye Disease (TED).

1 month ago - Business Wire

Here's Why Momentum Investors Will Love Horizon Therapeutics (HZNP)

Does Horizon Therapeutics (HZNP) have what it takes to be a top stock pick for momentum investors? Let's find out.

1 month ago - Zacks Investment Research

Why Is Horizon Therapeutics (HZNP) Up 3.7% Since Last Earnings Report?

Horizon Therapeutics (HZNP) reported earnings 30 days ago. What's next for the stock?

1 month ago - Zacks Investment Research